谁会被再入院?在妇科肿瘤人群中评估腹腔镜子宫切除再入院评分对机器人辅助子宫切除的作用
本研究为单机构回顾性队列研究,纳入2018年由妇科肿瘤医生行机器人子宫切除的423例女性,评估腹腔镜子宫切除再入院评分(LHRS)对30天再入院的预测作用。队列30天再入院率为4.5%,同日出院者再入院率为1.9%;LHRS≥3分者再入院比值高于低分者(OR 4.20,p=0.02)。作者认为LHRS适用于妇科肿瘤人群,处理术后感染风险因素或对LHRS≥3分者更密切随访可能减少再入院。
要点
- 423例机器人子宫切除患者中,30天再入院率为4.5%,同日出院者再入院率为1.9%。
- LHRS≥3分者再入院比值高于低分者(OR 4.20,p=0.02)。
- 感染性并发症占术后并发症、急诊就诊和再入院的大多数。
核心结论
- 微创子宫切除后再入院率低,LHRS≥3分与再入院风险增加相关。
- 研究结果支持LHRS适用于妇科肿瘤人群。
- 作者认为处理术后感染风险因素或对LHRS≥3分患者更密切随访可能减少术后再入院。
研究设计与样本
- 单机构回顾性队列研究,纳入2018年由妇科肿瘤医生行机器人子宫切除的423例女性。
- 采用逻辑回归评估术前、术中和术后因素与30天再入院、同日出院及术后并发症的关联。
主要发现
- 队列30天再入院率为4.5%,同日出院者再入院率为1.9%。
- 按LHRS评分,再入院率分别为:1分4.9%、2分7.8%、3分13.6%、4分16.7%。
- LHRS≥3分者再入院比值高于低分者(OR 4.20,p=0.02)。
- 感染性并发症占术后并发症、急诊就诊和再入院的大多数。
- 未发现可替代评分中术中和术后因素的术前因素。
关键数值与推荐
- LHRS包含糖尿病、慢性阻塞性肺疾病、播散性癌症、慢性类固醇使用、出血性疾病、手术时长及出院前任何术后并发症。
- LHRS≥3分者再入院比值高于低分者(OR 4.20,p=0.02)。
- 再入院率按LHRS评分:1分4.9%、2分7.8%、3分13.6%、4分16.7%。
临床怎么用
- 作者认为LHRS可用于妇科肿瘤人群,LHRS≥3分者再入院风险增加。
- 作者认为处理术后感染风险因素或对LHRS≥3分患者更密切随访可能减少术后再入院。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The laparoscopic hysterectomy readmission score (LHRS) was created to identify patients for whom same day discharge (SDD) after minimally invasive hysterectomy (MIH) may not be advisable and includes diabetes, chronic obstructive pulmonary disease, disseminated cancer, chronic steroid use, bleeding disorder, length of surgery, and any postoperative complication prior to discharge. We evaluated the performance of the score at predicting readmission in a gynecologic oncology population, and additionally sought to determine if any factors known prior to surgery could replace those that are not known until the time of surgery (operative time and postoperative complication). METHODS: This was a single-institution retrospective cohort study of women undergoing robotic hysterectomy by a gynecologic oncologist in 2018. Associations between pre-operative, operative and post-operative factors and 30-day readmission, SDD and postoperative complications were assessed using logistic regression. RESULTS: The 30-day readmission rate among the 423 women in the cohort was 4.5% and 1.9% in those undergoing SDD. Readmission rates by LHRS were: score 1 (4.9%), score 2 (7.8%), score 3 (13.6%), score 4 (16.7%). Patients with a LHRS of ≥3 had higher odds of readmission compared to those with a lower score (OR 4.20, p = 0.02). Infectious morbidity accounted for the majority of postoperative complications, emergency room visits and readmissions. We did not identify preoperative factors to replace the intra- and post-operative factors used in the score. CONCLUSIONS: The readmission rate following MIH is low, and a LHRS of ≥3 is associated with increased risk of readmission. Our findings support the applicability of the LHRS to a gynecologic oncology population; addressing risk factors for postoperative infection or closer follow up for patients with a LHRS ≥3 could reduce postoperative readmissions.
引用
- Lightfoot MDS, Felix AS, Bishop EE, et al. Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy. Gynecol Oncol. 2021. PMID: 34969534. doi:10.1016/j.ygyno.2021.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。